

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is⦠read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
$11.25
Price+0.85%
$0.10
$52.786m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$12.356m
-14.6%
1y CAGR+19.1%
3y CAGR+16.1%
5y CAGR-$3.06
-9.3%
1y CAGR+23.1%
3y CAGR+19.3%
5y CAGR-$13.513m
$14.964m
Assets$28.477m
Liabilities$5.725m
Debt38.3%
-0.5x
Debt to EBITDA-$1.345b
-13976.9%
1y CAGR-4640.0%
3y CAGR-3491.6%
5y CAGR